NEUMORA THERAPEUTICS, INC. Operating Cash Flow
NEUMORA THERAPEUTICS, INC. (NMRA) reported Operating Cash Flow of -$85.93 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- NEUMORA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$39.53M.
- NEUMORA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$46.40M.
- NEUMORA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$47.95M.
- NEUMORA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$46.63M.
- NEUMORA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$206.44M.
- NEUMORA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$182.94M.
- NEUMORA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$163.28M.
- NEUMORA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$114.90M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$39.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$85.93M 10-Q · filed 2026-08-14 | -$133.89M derived: sum of 3 quarters · filed 2026-08-14 | -$180.52M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$46.40M 10-Q · filed 2026-05-07 | -$94.36M derived: sum of 2 quarters · filed 2026-05-07 | -$140.99M derived: sum of 3 quarters · filed 2026-05-07 | -$193.40M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$47.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$94.59M derived: sum of 2 quarters · filed 2026-03-30 | -$146.99M derived: sum of 3 quarters · filed 2026-08-14 | -$206.44M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$46.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$99.04M derived: sum of 2 quarters · filed 2026-08-14 | -$158.49M 10-Q · filed 2025-11-06 | -$208.82M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$52.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$111.85M 10-Q · filed 2026-08-14 | -$162.19M derived: sum of 3 quarters · filed 2026-08-14 | -$195.68M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$59.45M 10-Q · filed 2026-05-07 | -$109.79M derived: sum of 2 quarters · filed 2026-05-07 | -$143.27M derived: sum of 3 quarters · filed 2026-05-07 | -$199.43M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$50.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$83.82M derived: sum of 2 quarters · filed 2026-03-30 | -$139.98M derived: sum of 3 quarters · filed 2026-03-30 | -$182.94M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$33.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$89.64M derived: sum of 2 quarters · filed 2025-11-06 | -$132.60M 10-Q · filed 2025-11-06 | -$184.04M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$56.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$99.11M 10-Q · filed 2025-08-06 | -$150.56M derived: sum of 3 quarters · filed 2025-08-06 | -$198.33M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$42.95M 10-Q · filed 2025-05-12 | -$94.40M derived: sum of 2 quarters · filed 2025-05-12 | -$142.17M derived: sum of 3 quarters · filed 2025-05-12 | -$173.19M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$51.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$99.22M derived: sum of 2 quarters · filed 2025-03-03 | -$130.24M derived: sum of 3 quarters · filed 2025-03-03 | -$163.28M 10-K · filed 2025-03-03 |
| 2023-09-30 | -$47.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$78.80M derived: sum of 2 quarters · filed 2024-11-12 | -$111.84M 10-Q · filed 2024-11-12 | -$142.20M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$31.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$64.06M 10-Q · filed 2024-08-06 | -$94.43M derived: sum of 3 quarters · filed 2025-03-03 | |
| 2023-03-31 | -$33.04M 10-Q · filed 2024-05-07 | -$63.41M derived: sum of 2 quarters · filed 2025-03-03 | ||
| 2022-12-31 | -$30.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$114.90M 10-K · filed 2025-03-03 | ||
| 2022-09-30 | -$84.53M 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |